Targeting KRAS in Pancreatic Cancer

被引：18

作者：

Cowzer, Darren ^{[1
]}

Zameer, Mohammed ^{[1
]}

Conroy, Michael ^{[1
]}

Kolch, Walter ^{[2
,3
]}

Duffy, Austin G. ^{[1
]}

机构：

[1] Mater Misericordiae Univ Hosp, Dept Med Oncol, Dublin D07R2WY, Ireland

[2] Univ Coll Dublin, Sch Med, Syst Biol Ireland, Belfield D04E1W1, Dublin, Ireland

[3] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Belfield D04E1W1, Dublin, Ireland

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2022年 / 12卷 / 11期

基金：

爱尔兰科学基金会;

关键词：

KRAS; pancreas cancer; targeted therapy; CELL LUNG-CANCER; ONCOGENIC KRAS; SOLID TUMORS; AMG; 510; INHIBITOR; THERAPY; COMBINATION; ADENOCARCINOMA; IMMUNOTHERAPY; GEMCITABINE;

D O I：

10.3390/jpm12111870

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.

引用

页数：11

共 73 条

[1] Advances in the Genetics and Biology of Pancreatic Cancer [J].

Aguirre, Andrew J. ;

Collisson, Eric A. .

CANCER JOURNAL, 2017, 23 (06) :315-320

[2] A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses [J].

Arbelaez, Carlos A. ;

Estrada, Juan ;

Gessner, Melissa A. ;

Glaus, Charles ;

Morales, Agnieszka B. ;

Mohn, Deanna ;

Phee, Hyewon ;

Lipford, J. Russell ;

Johnston, James A. .

NPJ VACCINES, 2020, 5 (01)

[3] Acquired Resistance to KRASG12C Inhibition in Cancer [J].

Awad, M. M. ;

Liu, S. ;

Rybkin, I. I. ;

Arbour, K. C. ;

Dilly, J. ;

Zhu, V. W. ;

Johnson, M. L. ;

Heist, R. S. ;

Patil, T. ;

Riely, G. J. ;

Jacobson, J. O. ;

Yang, X. ;

Persky, N. S. ;

Root, D. E. ;

Lowder, K. E. ;

Feng, H. ;

Zhang, S. S. ;

Haigis, K. M. ;

Hung, Y. P. ;

Sholl, L. M. ;

Wolpin, B. M. ;

Wiese, J. ;

Christiansen, J. ;

Lee, J. ;

Schrock, A. B. ;

Lim, L. P. ;

Garg, K. ;

Li, M. ;

Engstrom, L. D. ;

Waters, L. ;

Lawson, J. D. ;

Olson, P. ;

Lito, P. ;

Ou, S. -H. I. ;

Christensen, J. G. ;

Janne, P. A. ;

Aguirre, A. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) :2382-2393

[4] Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. [J].

Beatty, Gregory Lawrence ;

O'Hara, Mark H. ;

Nelson, Anne M. ;

McGarvey, Maureen ;

Torigian, Drew A. ;

Lacey, Simon F. ;

Melenhorst, Jan J. ;

Levine, Bruce ;

Plesa, Gabriela ;

June, Carl H. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[5] KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation [J].

Bekaii-Saab, Tanios S. ;

Spira, Alexander I. ;

Yaeger, Rona ;

Buchschacher, Gary L. ;

McRee, Autumn Jackson ;

Sabari, Joshua K. ;

Johnson, Melissa Lynne ;

Barve, Minal A. ;

Hafez, Navid ;

Velastegui, Karen ;

Christensen, James G. ;

Kheoh, Thian ;

Der-Torossian, Hirak ;

Rybkin, Igor I. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[6] Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes [J].

Biankin, Andrew V. ;

Waddell, Nicola ;

Kassahn, Karin S. ;

Gingras, Marie-Claude ;

Muthuswamy, Lakshmi B. ;

Johns, Amber L. ;

Miller, David K. ;

Wilson, Peter J. ;

Patch, Ann-Marie ;

Wu, Jianmin ;

Chang, David K. ;

Cowley, Mark J. ;

Gardiner, Brooke B. ;

Song, Sarah ;

Harliwong, Ivon ;

Idrisoglu, Senel ;

Nourse, Craig ;

Nourbakhsh, Ehsan ;

Manning, Suzanne ;

Wani, Shivangi ;

Gongora, Milena ;

Pajic, Marina ;

Scarlett, Christopher J. ;

Gill, Anthony J. ;

Pinho, Andreia V. ;

Rooman, Ilse ;

Anderson, Matthew ;

Holmes, Oliver ;

Leonard, Conrad ;

Taylor, Darrin ;

Wood, Scott ;

Xu, Qinying ;

Nones, Katia ;

Fink, J. Lynn ;

Christ, Angelika ;

Bruxner, Tim ;

Cloonan, Nicole ;

Kolle, Gabriel ;

Newell, Felicity ;

Pinese, Mark ;

Mead, R. Scott ;

Humphris, Jeremy L. ;

Kaplan, Warren ;

Jones, Marc D. ;

Colvin, Emily K. ;

Nagrial, Adnan M. ;

Humphrey, Emily S. ;

Chou, Angela ;

Chin, Venessa T. ;

Chantrill, Lorraine A. .

NATURE, 2012, 491 (7424) :399-405

[7] A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy [J].

Bodoky, Gyoergy ;

Timcheva, Constanta ;

Spigel, David Robert ;

La Stella, Phillip Joseph ;

Ciuleanu, Tudor Eliade ;

Pover, G. ;

Tebbutt, N. C. .

INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) :1216-1223

[8] Stable suppression of tumorigenicity by virus-mediated RNA interference [J].

Brummelkamp, TR ;

Bernards, R ;

Agami, R .

CANCER CELL, 2002, 2 (03) :243-247

[9] Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation [J].

Buday, Laszlo ;

Vas, Virag .

CANCER AND METASTASIS REVIEWS, 2020, 39 (04) :1067-1073

[10] Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma [J].

Aguirre, Andrew J. ;

Hruban, Ralph H. ;

Raphael, Benjamin J. .

CANCER CELL, 2017, 32 (02) :185-+

← 1 2 3 4 5 6 7 8 →